Cargando…

Th1Th17(CM) Lymphocyte Subpopulation as a Predictive Biomarker of Disease Activity in Multiple Sclerosis Patients under Dimethyl Fumarate or Fingolimod Treatment

Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quirant-Sánchez, Bibiana, Presas-Rodriguez, Silvia, Mansilla, María José, Teniente-Serra, Aina, Hervás-García, José V., Brieva, Luis, Moral-Torres, Ester, Cano, Antonio, Munteis, Elvira, Navarro-Barriuso, Juan, Martínez-Cáceres, Eva M., Ramo-Tello, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617925/ https://www.ncbi.nlm.nih.gov/pubmed/31346315 http://dx.doi.org/10.1155/2019/8147803

Ejemplares similares

Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment
por: Mansilla, María José, et al.
Publicado: (2019)

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis
por: Quirant-Sánchez, Bibiana, et al.
Publicado: (2021)

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4(+) Cells Towards a Functional Hyporesponsiveness
por: Navarro-Barriuso, Juan, et al.
Publicado: (2021)

MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients
por: Navarro-Barriuso, Juan, et al.
Publicado: (2019)

Comparative transcriptomic profile of tolerogenic dendritic cells differentiated with vitamin D3, dexamethasone and rapamycin
por: Navarro-Barriuso, Juan, et al.
Publicado: (2018)

Identifying Changes in Peripheral Lymphocyte Subpopulations in Adult Onset Type 1 Diabetes
por: Teniente-Serra, Aina, et al.
Publicado: (2021)

Increased Natural Killer Cells Are Associated with Alcohol Liver Fibrosis and with T Cell and Cytotoxic Subpopulations Change
por: Zuluaga, Paola, et al.
Publicado: (2022)

Assessing Blood-Based Biomarkers to Define a Therapeutic Window for Natalizumab
por: Granell-Geli, Júlia, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
por: Sancho-Saldaña, Agustín, et al.
Publicado: (2022)

Characterization of recent thymic emigrants (RTEs), transitional B and Th17 cells in multiple sclerosis (MS)
por: Teniente-Serra, Aina, et al.
Publicado: (2011)

Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator
por: Mansilla, María José, et al.
Publicado: (2021)

Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy
por: Mansilla, M. J., et al.
Publicado: (2021)

SARS-CoV-2: una nueva amenaza
por: López Rodríguez, Cristina A., et al.
Publicado: (2020)

SARS-CoV-2: a new threat
por: López Rodríguez, Cristina A., et al.
Publicado: (2020)

Cryopreserved vitamin D(3)-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients
por: Mansilla, María José, et al.
Publicado: (2016)

Impaired T-cell migration to the CNS under fingolimod and dimethyl fumarate
por: Mathias, Amandine, et al.
Publicado: (2017)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
por: Vollmer, Brandi, et al.
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Diagnostic value of different anti-citrullinated peptides antibodies in rheumatoid arthritis
por: Ruiz-Ortiz de Arrizabaleta, Estíbaliz, et al.
Publicado: (2011)

Epstein-Barr Virus and Multiple Sclerosis: A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers
por: Ortega-Hernandez, Oscar-Danilo, et al.
Publicado: (2023)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
por: Blumenfeld Kan, S, et al.
Publicado: (2019)

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study
por: Diem, Lara, et al.
Publicado: (2020)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
por: Willekens, Barbara, et al.
Publicado: (2019)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up
por: Hersh, Carrie M, et al.
Publicado: (2017)

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
por: Rupp, Tristan, et al.
Publicado: (2022)

Fingolimod Therapy in Multiple Sclerosis Leads to the Enrichment of a Subpopulation of Aged NK Cells
por: Schwichtenberg, Svenja C., et al.
Publicado: (2021)

Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses
por: Ramo-Tello, Cristina, et al.
Publicado: (2021)

Involvement of CD26 in Differentiation and Functions of Th1 and Th17 Subpopulations of T Lymphocytes
por: Zhao, Xiangli, et al.
Publicado: (2021)

Searching for the Transcriptomic Signature of Immune Tolerance Induction—Biomarkers of Safety and Functionality for Tolerogenic Dendritic Cells and Regulatory Macrophages
por: Navarro-Barriuso, Juan, et al.
Publicado: (2018)

Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro
por: Yang, Xia, et al.
Publicado: (2011)

Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
por: Hersh, Carrie M, et al.
Publicado: (2020)

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
por: Delgado, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hdst0l9o4caliddha8tmthtptr